Using Tebentafusp to treat metastatic uveal melanoma
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 7th, 2024
|
Tirzepatide, widely used for diabetes management owing to its insulin-boosting capabilities, has demonstrated a tendency for weight loss in individuals undergoing treatment. Thus, a recent study, featured in the Journal of the American Medical Association, had looked into the impact of Tirzepatide's long-term use on weight management.
The phase 3 clinical trial involved 670 participants with a body mass index greater than 30 or greater than 27 if they had at least one other obesity-related condition, such as hypertension or dyslipidemia. Participants received a weekly subcutaneous injection of Tirzepatide for 36 weeks, starting at 2.5 mg in the first week and increasing by 2.5 mg each week until reaching a maximum tolerated dose of 10 mg or 15 mg. At the end of the initial 36 weeks, participants were randomly assigned to either discontinue Tirzepatide and switch to a placebo or continue treatment for another 52 weeks. Over the 88-week study, those receiving continuous Tirzepatide treatment saw a 5.5% reduction in body weight, while those who stopped at the 36th week experienced a 16.6% increase in body weight. Examining the change in body weight from the study's beginning to end revealed a 25.3% reduction in the Tirzepatide group and a 9.9% loss in the placebo group.
The phase 3 clinical trial involved 670 participants with a body mass index greater than 30 or greater than 27 if they had at least one other obesity-related condition, such as hypertension or dyslipidemia. Participants received a weekly subcutaneous injection of Tirzepatide for 36 weeks, starting at 2.5 mg in the first week and increasing by 2.5 mg each week until reaching a maximum tolerated dose of 10 mg or 15 mg. At the end of the initial 36 weeks, participants were randomly assigned to either discontinue Tirzepatide and switch to a placebo or continue treatment for another 52 weeks. Over the 88-week study, those receiving continuous Tirzepatide treatment saw a 5.5% reduction in body weight, while those who stopped at the 36th week experienced a 16.6% increase in body weight. Examining the change in body weight from the study's beginning to end revealed a 25.3% reduction in the Tirzepatide group and a 9.9% loss in the placebo group.